Literature DB >> 11577123

Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.

F Roberts1, A E McCall, R A Burnett.   

Abstract

AIMS: The diagnosis of malignant mesothelioma in pleural biopsies can be difficult. Survival is short and consequently many of these cases are submitted to necropsy to assist with medicolegal claims. This study compares the histological appearances and immunohistochemical profile of nine biopsy specimens with corresponding postmortem specimens.
METHODS: Archival, formalin fixed, paraffin wax embedded material was obtained from nine biopsy and corresponding postmortem cases of malignant mesothelioma. The specimens were examined by light microscopy and stained with an immunohistochemical panel of 12 commercially available antibodies including CAM5.2, HBME-1, and Ber-EP4, and antibodies to thrombomodulin, calretinin, CD44H, WT-1, carcinoembryonic antigen, Leu-M1, epithelial membrane antigen and p53.
RESULTS: There was greater variation in the range of histological appearances of mesotheliomas in postmortem specimens compared with biopsy specimens. There was also variability in the immunohistochemical staining pattern for certain antibodies including HBME-1, and Ber-EP4 and antibodies to calretinin, CD44H, WT-1, and p53.
CONCLUSIONS: All available information should be taken into account in the histological diagnosis of malignant mesothelioma. Interpretation of the immunohistochemical profile should be regarded with some caution when only postmortem material is available. When reporting a postmortem case of suspected mesothelioma, the pathologist should seek to review all available biopsy material in conjunction with the necropsy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11577123      PMCID: PMC1731284          DOI: 10.1136/jcp.54.10.766

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  16 in total

Review 1.  Pathology of malignant mesothelioma.

Authors:  R L Attanoos; A R Gibbs
Journal:  Histopathology       Date:  1997-05       Impact factor: 5.087

Review 2.  The immunohistochemical diagnosis of epithelial mesothelioma.

Authors:  N G Ordóñez
Journal:  Hum Pathol       Date:  1999-03       Impact factor: 3.466

3.  Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms.

Authors:  R L Attanoos; S D Dojcinov; R Webb; A R Gibbs
Journal:  Histopathology       Date:  2000-09       Impact factor: 5.087

4.  The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.

Authors:  N G Ordóñez
Journal:  Am J Surg Pathol       Date:  1997-12       Impact factor: 6.394

5.  Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.

Authors:  P M Cury; D N Butcher; C Fisher; B Corrin; A G Nicholson
Journal:  Mod Pathol       Date:  2000-02       Impact factor: 7.842

6.  Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.

Authors:  P R Wirth; J Legier; G L Wright
Journal:  Cancer       Date:  1991-02-01       Impact factor: 6.860

7.  Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.

Authors:  R W Brown; G M Clark; A K Tandon; D C Allred
Journal:  Hum Pathol       Date:  1993-04       Impact factor: 3.466

8.  Diffuse malignant pleural mesothelioma in Glasgow.

Authors:  A J Dorward; B H Stack
Journal:  Br J Dis Chest       Date:  1981-10

9.  The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis.

Authors:  B G Skov; A F Lauritzen; F Hirsch; H W Nielsen
Journal:  Histopathology       Date:  1994-06       Impact factor: 5.087

10.  Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation.

Authors:  C J Fisher; C E Gillett; B Vojtĕsek; D M Barnes; R R Millis
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

View more
  5 in total

Review 1.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

2.  A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.

Authors:  Hila Benjamin; Danit Lebanony; Shai Rosenwald; Lahav Cohen; Hadas Gibori; Naama Barabash; Karin Ashkenazi; Eran Goren; Eti Meiri; Sara Morgenstern; Marina Perelman; Iris Barshack; Yaron Goren; Tina Bocker Edmonston; Ayelet Chajut; Ranit Aharonov; Zvi Bentwich; Nitzan Rosenfeld; Dalia Cohen
Journal:  J Mol Diagn       Date:  2010-09-23       Impact factor: 5.568

3.  Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry.

Authors:  Helmut P Sandeck; Oluf D Røe; Kristina Kjærheim; Helena Willén; Erik Larsson
Journal:  Diagn Pathol       Date:  2010-07-06       Impact factor: 2.644

4.  Application of proteomics to soft tissue sarcomas.

Authors:  Tadashi Kondo; Daisuke Kubota; Akira Kawai
Journal:  Int J Proteomics       Date:  2012-06-19

5.  Desmoplastic small round cell tumour: Cytological and immunocytochemical features.

Authors:  Nara M Granja; Maria D Begnami; Jeni Bortolan; Adhemar Longatto Filho; Fernando C Schmitt
Journal:  Cytojournal       Date:  2005-03-18       Impact factor: 2.091

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.